Skip to Content

Hexavac

Active Substance: purified diphtheria toxoid / purified tetanus toxoid / purified pertussis toxoid / purified pertussis filamentous haemagglutinin / hepatitis B surface antigen / inactivated type 1 poliovirus (Mahoney) / inactivated type 2 poliovirus (MEF 1) / inactivated type 3 poliovirus (Saukett) / Haemophilus influenzae type b polysaccharide
Common Name: diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted
ATC Code: J07CA
Marketing Authorisation Holder: Sanofi Pasteur MSD, SNC
Active Substance: purified diphtheria toxoid / purified tetanus toxoid / purified pertussis toxoid / purified pertussis filamentous haemagglutinin / hepatitis B surface antigen / inactivated type 1 poliovirus (Mahoney) / inactivated type 2 poliovirus (MEF 1) / inactivated type 3 poliovirus (Saukett) / Haemophilus influenzae type b polysaccharide
Status: Withdrawn
Authorisation Date: 2000-10-23
Therapeutic Area: Meningitis, Haemophilus Hepatitis B Diphtheria Poliomyelitis Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

This combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis B caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

The marketing authorisation for Hexavac has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide